IDXX

SEC source: 0001567619-19-015977 · doc1.xml · derivative · entry 10

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,820

Underlying: Common Stock · 10,000 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,942

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $261.36 to a high of $262.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,027,942

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $260.07 to a high of $261.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,032,142

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $259.05 to a high of $260.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,034,542

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $258.21 to a high of $258.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,542

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $256.28 to a high of $257.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 26 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2019.

SEC source: 0001567619-19-015984 · doc1.xml · derivative · entry 6

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,666

Underlying: Common Stock · 6,056 shares

Expires 2025-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 4, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015984 · doc1.xml · derivative · entry 5

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,988 shares

Expires 2024-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 4

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 3

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

SEC source: 0001567619-19-015984 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015981 · doc1.xml · derivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,780

Underlying: Common Stock · 961 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020.

F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning July 24, 2020.

SEC source: 0001567619-19-015981 · doc1.xml · derivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,058 shares

Expires 2029-08-04

F4 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning August 5, 2020.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 18

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,435

Underlying: Common Stock · 1,999 shares

Expires 2028-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F11 · derivative.exercise_date: Grant of option to buy 9,434 shares of Issuer common stock that vest in five annual installments beginning February 14, 2019.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 17

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,948

Underlying: Common Stock · 4,438 shares

Expires 2027-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F10 · derivative.exercise_date: Grant of option to buy 10,386 shares of Issuer common stock that vest in five annual installments beginning February 14, 2018.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 16

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,559

Underlying: Common Stock · 6,190 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 10,749 shares of Issuer common stock that vest in five annual installments beginning February 14, 2017.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 15

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,069

Underlying: Common Stock · 3 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy 2,072 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2019, respectively, and as to the remainder on February 14, 2021.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 14

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,226

Underlying: Common Stock · 136 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F7 · derivative.exercise_date: Grant of option to buy 1,181 shares of Issuer common stock that vest in five annual installments beginning February 14, 2016 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 13

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 748

Underlying: Common Stock · 638 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F6 · derivative.exercise_date: Grant of option to buy 693 shares of Issuer common stock that vest in five annual installments beginning February 14, 2016 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015979 · doc1.xml · derivative · entry 12

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,010 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F5 · derivative.exercise_date: Grant of option to buy 1,005 shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 10

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,425

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $264.62 to a high of $265.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 9

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,772

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 8

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,319

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $263.60 to a high of $264.54 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 7

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 6

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,387

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 5

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,949

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 4

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,759

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 3

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 2

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-015979 · doc1.xml · nonDerivative · entry 1

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 20 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2019.

SEC source: 0001567619-19-015623 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-015622 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,789

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-015621 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 719

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-012690 · doc1.xml · derivative · entry 4

Turner Kathy V · CIK 0001740719 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,012

Underlying: Common Stock · 466 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F5 · price: Not applicable.

F4 · derivative.exercise_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F4 · derivative.expiration_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

SEC source: 0001567619-19-012690 · doc1.xml · nonDerivative · entry 2

Turner Kathy V · CIK 0001740719 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,212

F2 · price: Closing price of Issuer's common stock on the NASDAQ market on May 31, 2019.

SEC source: 0001567619-19-012690 · doc1.xml · nonDerivative · entry 1

Turner Kathy V · CIK 0001740719 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 32 shares of Issuer common stock purchased under the IDEXX Employee Stock Purchase Plan on March 29, 2019.

SEC source: 0001567619-19-012689 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,595

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $249.50 to a high of $250.3250 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001567619-19-011316 · doc1.xml · derivative · entry 3

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,790 shares

Expires 2023-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,395 shares on May 8, 2014, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-011316 · doc1.xml · nonDerivative · entry 2

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,696

SEC source: 0001567619-19-011316 · doc1.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-010601 · doc1.xml · nonDerivative · entry 1

Lane Michael · CIK 0001740689 · Corporate Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,952

F1 · balance_after: Includes 32 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019.

SEC source: 0001567619-19-010456 · doc1.xml · derivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010456 · doc1.xml · derivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,371

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010455 · doc1.xml · derivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010455 · doc1.xml · derivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,145

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010454 · doc1.xml · derivative · entry 2

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010454 · doc1.xml · derivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,147

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-010453 · doc1.xml · derivative · entry 2

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.